Autoimmune & Arthritis
Diabetes Drug Metformin Shows Promise for HIV Suppression and Immune Control
New research reveals metformin can silence HIV and boost immune control, offering hope for treatment-free remission.
Research Paper
Mar 28, 2026 3
Results for "Metformin TAME Trial" in Auto-Immunity
20 articles
Autoimmune & Arthritis
Redosing Diabetes Drug Shows No Added Benefit in Breakthrough Mouse Study
New research reveals why giving multiple doses of a promising type 1 diabetes treatment doesn't improve outcomes beyond a single course.
Research Paper
Mar 29, 2026 2
Autoimmune & Arthritis
Gilead Tests Vesatolimod as HIV Immune Activator in Controlled Patients on ART
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
Clinical Trial
Jun 19, 2026 0
Autoimmune & Arthritis
PI vs NNRTI Regimens Face Off in Severely Immunocompromised HIV Patients
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
Clinical Trial
Jun 18, 2026 0
Autoimmune & Arthritis
Thymosin Alpha-1 Cuts Sepsis Death Risk But Only in Specific Patient Subgroups
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
Research Paper
Apr 27, 2026 0
Autoimmune & Arthritis
Couples-Based HIV Prevention Program Tests PrEP Adherence and Stigma Reduction in South Africa
A cluster randomized trial tests whether couples counseling plus stigma workshops can boost PrEP/ART uptake among young South African adults.
Clinical Trial
May 14, 2026 0
Autoimmune & Arthritis
New Rheumatoid Arthritis Drug Shows Promise for Treatment-Resistant Patients
Phase 3 trial tests otilimab against standard care in 550 patients who failed previous biologics and JAK inhibitors.
Clinical Trial
Mar 28, 2026 3
Autoimmune & Arthritis
NMN Treats Immune Thrombocytopenia by Restoring NAD+ in Macrophages
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Research Paper
Apr 30, 2026 0
Autoimmune & Arthritis
Triple vs Dual HIV Therapy Compared for Immune Activation Control
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
Clinical Trial
Jun 2, 2026 0
Autoimmune & Arthritis
Terminated COVID-19 Trial Leaves Maraviroc and Favipiravir Questions Unanswered
A Phase 2 trial testing maraviroc and favipiravir for severe COVID-19 was terminated before completion, leaving efficacy data incomplete.
Clinical Trial
Jun 5, 2026 0
Autoimmune & Arthritis
Five-Drug HAART Cocktail Targets HIV Eradication in 40 Patients
A German proof-of-concept trial tests whether a maximal five-class antiretroviral regimen can deplete latent HIV reservoirs.
Clinical Trial
Jun 4, 2026 0
Autoimmune & Arthritis
Targeted Gout Treatment Beats Symptom-Based Care in Major Dutch Trial
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
Research Paper
Mar 28, 2026 0
Autoimmune & Arthritis
GSK2878175 Shows Early Promise Against Hepatitis C in Phase 1 Dose-Escalation Trial
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Clinical Trial
Jun 15, 2026 0
Autoimmune & Arthritis
JAK Inhibitor Tofacitinib Shows Promise for Lupus Treatment in Safety Trial
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Clinical Trial
Mar 28, 2026 4
Autoimmune & Arthritis
Anti-CD3 Treatment Reprograms Immune Cells to Prevent Type 1 Diabetes
New research reveals how a single antibody treatment creates lasting protection against autoimmune diabetes by reshaping immune cells.
Research Paper
Mar 29, 2026 1
Autoimmune & Arthritis
Anti-CD38 Antibody CM313 Lifts Platelet Counts in 83% of Refractory ITP Patients
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Research Paper
Jun 12, 2026 0
Autoimmune & Arthritis
Early Rheumatoid Arthritis Treatment Shows Promise for Rapid Remission
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
Clinical Trial
Mar 28, 2026 3
Autoimmune & Arthritis
JAK Inhibitor Tofacitinib Shows Promise Against Rheumatoid Arthritis in Phase 3 Trial
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
Clinical Trial
Mar 28, 2026 0
Autoimmune & Arthritis
New Drug KPL-404 Shows Promise for Treatment-Resistant Rheumatoid Arthritis
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Clinical Trial
Mar 28, 2026 3
Autoimmune & Arthritis
Kidney Transplant Rejection Treatments Reviewed as Phase 3 Trials Offer New Hope
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
Research Paper
Jun 6, 2026 0
Page 1 of 2Next